Lipid Signaling Pathways in Cancer

项目总结/摘要 本申请寻求对两年一次的科学会议系列的支持 题为“癌症中的脂质信号通路”。这些会议由以下机构赞助： 美国实验生物学学会联合会（FASEB） 两年一度的夏季研究会议（SRC）系列的一部分，并共同 由马约临床医学院的艾伦·P·菲尔兹博士和 宾夕法尼亚大学医学院的Marcelo Kazanietz说。的 下一次会议将于7月在亚利桑那州无忧无虑的无忧无虑度假村举行 2009年19-24日，随后的会议定于2011年夏季举行， 2013年夏天。通过本申请提供的资助将用于 部分资助注册费和旅费的费用， 研究人员，包括研究生和博士后研究员，邀请 在这些会议上介绍他们的工作。会议在课程期间举行 为期4天，有30多位受邀的外地领导人出席， 这是癌症研究领域的最新突破。最近 脂质信号传导领域的令人兴奋的发展将被提出， 强化了脂质介质在启动和 癌症的进展。例如，蛋白质中的肿瘤特异性遗传改变 参与磷酸肌醇和PKC信号转导已被发现在许多人 癌症，强调了这些脂质信号通路的重要性， 肿瘤发生PI 3-K/Akt/mTOR、PKC、DAG依赖性 GTP酶、Ras家族GTP酶的脂质修饰和鞘磷脂酶 信号和这些途径在肿瘤发生中的作用也将被讨论。 许多这些脂质信号通路是有吸引力的候选人的发展 癌症治疗的新策略。事实上， 目前正在评估针对这些脂质信号通路的药物 在诊所里因此，将特别强调翻译研究 脂质信号通路可能导致有希望的新的临床癌症 治疗。鉴于这一肥沃的研究领域的迅速发展， 会议日程安排是合适的。无其他定期会议 关注这一新兴领域，这一系列会议将成为 有效科学交流的主要论坛，将有助于促进 未来五年在这一领域取得的进展。

Project Summary/Abstract This application seeks support for a biennial scientific conference series entitled 'Lipid Signaling Pathways in Cancer'. The conferences are sponsored by the Federation of the American Societies for Experimental Biology (FASEB) as part of their biennial Summer Research Conference (SRC) Series and are co- organized by Dr. Alan P. Fields of the Mayo Clinic College of Medicine and Dr. Marcelo Kazanietz of the University of Pennsylvania School of Medicine. The next conference will be held at the Carefree Resort in Carefree, Arizona on July 19-24, 2009 with subsequent conferences scheduled for summer of 2011 and summer 2013. Support provided through funding of this application will be used to partially finance the costs of registration fees and travel expenses for junior investigators, including graduate students and post-doctoral fellows, invited to present their work at these conferences. The conference is held over the course of 4 days, with more than 30 invited leaders in the field attending to present the latest breakthroughs in this highly relevant area of cancer research. Recent exciting developments in the field of lipid signaling will be presented that have reinforced the concept that lipid mediators play key roles in the initiation and progression of cancer. For example, tumor-specific genetic alterations in proteins involved in phosphoinositide and PKC signaling have been found in many human cancers, highlighted the importance of these lipid signaling pathways in tumorigenesis. Exciting findings in PI 3-K/Akt/mTOR, PKC, DAG-dependent GTPases, lipid modifications of Ras family GTPases, and sphingomyelinase signaling and the role of these pathways in tumorigenesis will also be discussed. Many of these lipid signaling pathways are attractive candidates for development of novel therapeutic strategies for cancer treatment. Indeed, novel therapeutics that target several of these lipid signaling pathways are currently being evaluated in the clinic. Particular emphasis will therefore be placed on translational studies of lipid signaling pathways that may lead to promising new clinical cancer treatments. Given the rapid developments in this fertile research area, a biennial meeting schedule is appropriate. No other regularly scheduled conference focuses on this burgeoning area, and this conference series is poised to become a major forum for effective scientific interchange that will serve to facilitate advances in this field over the next five years.